Regnase-1 overexpression as a therapeutic approach of Marfan syndrome.

Authors:
Noormalal M; Schmiedel N; Bozoglu T; Matzen A; Hille S and 13 more

Journal:
Mol Ther Methods Clin Dev

Publication Year: 2023

DOI:
10.1016/j.omtm.2023.101163

PMCID:
PMC10762926

PMID:
38178915

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Mol Ther Methods Clin Dev

Abbreviation: Mol Ther Methods Clin Dev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine, Research & Experimental

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
AAV8 gene therapy reverses cardiac pathology and prevents early mortality in a mouse model of Fried…
Chang JC; Ryan MR; Stark MC and 16 more (2024) - Transparency Score: 3/6
AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenic…
Doshi BS; Samelson-Jones BJ; Nichols TC and 6 more (2024) - Transparency Score: 3/6
A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mu…
Zhang J; Frabutt DA; Chrzanowski M and 9 more (2024) - Transparency Score: 3/6
B cell focused transient immune suppression protocol for efficient AAV readministration to the live…
Rana J; Herzog RW; Muñoz-Melero M and 9 more (2024) - Transparency Score: 3/6
Continuous manufacturing of lentiviral vectors using a stable producer cell line in a fixed-bed bio…
Stibbs DJ; Silva Couto P; Takeuchi Y and 3 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of interests T.B. and C.K. have previously filed a patent application on the polymer coating for the vascular targeting of AAVs. The other authors declare no competing interests."

Evidence found in paper:

"This project received funding from the European Union’s 10.13039/501100007601Horizon 2020 research and innovation program under grant agreement no. 825670 (to O.J.M.) and the 10.13039/100010447German Centre for Cardiovascular Research (DZHK) (81Z0700206, to O.J.M.)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025